SCHEMBL3662480

SCHEMBL3662480

CCOc1cccc(-c2cncc(-c3cc(CN)nc(-c4ccccn4)c3)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP19A1 P11511 1/20 0.43
S1PR1 P21453 5/20 0.43
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
FGFR2 P21802 2/20 0.41
FGFR3 P22607 2/20 0.41
FGFR1 P11362 1/20 0.41
FFAR1 O14842 2/20 0.39
CBFB Q13951 1/20 0.39
MAP4K4 O95819 1/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
NOTUM Q6P988 1/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
GRM5 P41594 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666895 0.92 NPC1 (0.47) CYP11B1CYP11B2CYP19A1MAPTNPSR1
SCHEMBL2241181 0.87 FFAR1 (0.48) CYP11B1CYP11B2CYP19A1S1PR1MAPT
SCHEMBL3665665 0.82 CYP19A1 (0.42) CYP11B1CYP11B2CYP19A1MAPTFFAR1
SCHEMBL3664279 0.81 LOXL2 (0.46) CBFBPRMT5WDR77
SCHEMBL3663471 0.81 MEN1 (0.41) MAPTFFAR1NPC1RAB9ASMN1; SMN2
SCHEMBL3662834 0.79 KDM4E (0.41) CYP11B1CYP11B2FFAR1NPC1PKM
SCHEMBL2238718 0.79 FFAR1 (0.54) CYP11B1CYP11B2CYP19A1FFAR1NPC1
SCHEMBL3663615 0.78 CCR1 (0.37) CYP19A1NPSR1PRMT5WDR77NPC1
SCHEMBL3663465 0.77 ADORA3 (0.47) CYP11B1CYP11B2FFAR1NPC1PKM
SCHEMBL3664993 0.77 CCR1 (0.34) CYP19A1PRMT5WDR77NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CYP11B1 16/4885CYP11B2 26/4885CYP19A1 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.